Merger and acquisition (M A) deals in Chinese medicine production industry reached 149 in number in the first half of 2015, up 36 percent year on year, as the December 31 deadline for newly revised standard of Good Manufacturing Practice (GMP) certification approaches.
Chen Juan, a researcher with CCID Think Tank under the Ministry of Industry and Information Technology said that with higher requirement on production facilities and management skills, the new GMP will help accelerate the elimination of small and medium sized medicine production enterprises, and provide M A opportunities for leading companies in this field.
According to Chen, the increase of M A has optimized the industrial structure and raised industrial concentration in medicine production field. The proportion of biopharmaceuticals grew while that of chemical medicine decreased.
As for high-capacity injection production, the top 5 production firms now take some 50 percent market shares in China.
Latest comments